EWSR1 and Ewing sarcoma: Sankar et al. demonstrated that a non-competitive LSD1 inhibitor, HCI2509, disrupted transcriptional profiles and malignant characteristics of EWS/FLI- and EWS/ERG-containing Ewing sarcoma [15] in preclinical evaluations.